123 related articles for article (PubMed ID: 7748464)
1. Intranigral injected iron progressively reduces striatal dopamine metabolism.
Wesemann W; Blaschke S; Solbach M; Grote C; Clement HW; Riederer P
J Neural Transm Park Dis Dement Sect; 1994; 8(3):209-14. PubMed ID: 7748464
[TBL] [Abstract][Full Text] [Related]
2. Effect of lazaroid U-74389G on iron-induced reduction of striatal dopamine metabolism.
Wesemann W; Solbach M; Nafe R; Grote C; Sontag KH; Riederer P; Jellinger K; Mennel HD; Clement HW
J Neural Transm Suppl; 1995; 46():175-82. PubMed ID: 8821053
[TBL] [Abstract][Full Text] [Related]
3. Intranigral substance P stimulation of striatal dopamine release is inhibited by spantide II: a new tachykinin antagonist without apparent neurotoxicity.
Reid MS; Hökfelt T; Herrera-Marschitz M; Håkanson R; Feng DM; Folkers K; Goldstein M; Ungerstedt U
Brain Res; 1990 Nov; 532(1-2):175-81. PubMed ID: 1704289
[TBL] [Abstract][Full Text] [Related]
4. Differential effects of tachykinins injected intranigrally on striatal dopamine metabolism.
Tan DP; Tsou K
J Neurochem; 1988 Nov; 51(5):1333-7. PubMed ID: 2459306
[TBL] [Abstract][Full Text] [Related]
5. Effects of intranigral administration of dopamine agonists and antagonists and baclofen on concentrations of dopac and dopamine in the striatum and substantia nigra of the rat.
Wuerthele SM; Friedle NM; Moore KE
J Neural Transm; 1979; 45(2):117-27. PubMed ID: 469523
[TBL] [Abstract][Full Text] [Related]
6. Effects of intranigral substance P and neurokinin A on striatal dopamine release--I. Interactions with substance P antagonists.
Reid MS; Herrera-Marschitz M; Hökfelt T; Ohlin M; Valentino KL; Ungerstedt U
Neuroscience; 1990; 36(3):643-58. PubMed ID: 1700329
[TBL] [Abstract][Full Text] [Related]
7. Early increase in dopamine release in the ipsilateral striatum after unilateral intranigral administration of lactacystin produces spontaneous contralateral rotations in rats.
Konieczny J; Lenda T; Czarnecka A
Neuroscience; 2016 Jun; 324():92-106. PubMed ID: 26964686
[TBL] [Abstract][Full Text] [Related]
8. Effect of trihexyphenidyl, a non-selective antimuscarinic drug, on decarboxylation of L-dopa in hemi-Parkinson rats.
Izurieta-Sánchez P; Sarre S; Ebinger G; Michotte Y
Eur J Pharmacol; 1998 Jul; 353(1):33-42. PubMed ID: 9721037
[TBL] [Abstract][Full Text] [Related]
9. Striatal dopamine and glutamate release: effects of intranigral injections of substance P.
Reid MS; Herrera-Marschitz M; Kehr J; Ungerstedt U
Acta Physiol Scand; 1990 Dec; 140(4):527-37. PubMed ID: 1707211
[TBL] [Abstract][Full Text] [Related]
10. Effect of lazaroid pretreatment on dopamine-induced impairment of the rat nigrostriatal system.
Clement HW; Grote C; Heiser P; Wesemann W
J Neural Transm (Vienna); 2002 May; 109(5-6):673-82. PubMed ID: 12111459
[TBL] [Abstract][Full Text] [Related]
11. Bilateral dopamine metabolism in the striatum after unilateral application of tetrodotoxine in the midbrain of the rat.
Korf J; Postema F
Brain Res; 1980 Apr; 187(1):251-5. PubMed ID: 7357473
[No Abstract] [Full Text] [Related]
12. Cobalt injections into the substantia nigra of the rat: effects on behavior and dopamine metabolism in the striatum.
Shibuya M; Fariello R; Farley IJ; Price KS; Lloyd KG; Hornykiewicz O
Exp Neurol; 1978 Feb; 58(3):486-99. PubMed ID: 620704
[No Abstract] [Full Text] [Related]
13. Biochemical lesions of the nigrostriatal system by TaClo (1-trichloromethyl-1,2,3,4-tetrahydro-beta-carboline) and derivatives.
Grote C; Clement HW; Wesemann W; Bringmann G; Feineis D; Riederer P; Sontag KH
J Neural Transm Suppl; 1995; 46():275-81. PubMed ID: 8821064
[TBL] [Abstract][Full Text] [Related]
14. Influence of selective inhibition of monoamine oxidase A or B on striatal metabolism of L-DOPA in hemiparkinsonian rats.
Finberg JP; Wang J; Goldstein DS; Kopin IJ; Bankiewicz KS
J Neurochem; 1995 Sep; 65(3):1213-20. PubMed ID: 7643100
[TBL] [Abstract][Full Text] [Related]
15. Intranigral injection of selective neurokinin-1 and neurokinin-3 but not neurokinin-2 receptor agonists biphasically modulate striatal dopamine metabolism but not striatal preprotachykinin-A mRNA in the rat.
Humpel C; Saria A
Neurosci Lett; 1993 Jul; 157(2):223-6. PubMed ID: 7694197
[TBL] [Abstract][Full Text] [Related]
16. Nicotine prevents striatal dopamine loss produced by 6-hydroxydopamine lesion in the substantia nigra.
Costa G; Abin-Carriquiry JA; Dajas F
Brain Res; 2001 Jan; 888(2):336-342. PubMed ID: 11150495
[TBL] [Abstract][Full Text] [Related]
17. Therapy of Morbus Parkinson and radical-induced neurotoxicity in the rat--in vivo voltammetric studies.
Wesemann W
J Neural Transm Suppl; 1992; 38():45-53. PubMed ID: 1283403
[TBL] [Abstract][Full Text] [Related]
18. Microdialysis study of the effects of the antiparkinsonian drug budipine on L-DOPA-induced release of dopamine and 5-hydroxytryptamine by rat substantia nigra and corpus striatum.
Biggs CS; Starr MS
Synapse; 1999 Oct; 34(1):36-46. PubMed ID: 10459170
[TBL] [Abstract][Full Text] [Related]
19. Sensorimotor impairment and elevated levels of dopamine metabolites in the neostriatum occur rapidly after intranigral injection of 6-hydroxydopamine or gamma-hydroxybutyrate in awake rats.
Altar CA; O'Neil S; Marshall JF
Neuropharmacology; 1984 Mar; 23(3):309-18. PubMed ID: 6427648
[TBL] [Abstract][Full Text] [Related]
20. Dopaminergic functional supersensitivity: effects of chronic L-dopa and carbidopa treatment in an animal model of Parkinson's disease.
Hossain MA; Weiner N
J Pharmacol Exp Ther; 1993 Dec; 267(3):1105-11. PubMed ID: 8263772
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
